An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.

Publication/Presentation Date



INTRODUCTION: Neuroendocrine neoplasms (NENs) are a broad category of rare neoplasms originating from the neuroendocrine cells in various organs. NENs encompass a spectrum of tumors, including neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), which differ in their biological behavior and prognosis. NETs are generally well-differentiated and slow-growing, while NECs are poorly differentiated and more aggressive. The management of NETs often involves the use of somatostatin analogs, such as octreotide and lanreotide, to control tumor growth and alleviate associated symptoms, particularly in the case of well-differentiated NETs. Lanreotide is indicated to control tumor growth, while both lanreotide and octreotide are indicated to alleviate associated symptoms. However, the treatment approach may vary depending on the specific type and grade of the neuroendocrine neoplasm.

AREAS COVERED: Through a comprehensive review of clinical trials, post-marketing surveillance, real-world evidence, and the safety profile of lanreotide autogel, this review provides an update on the safety of lanreotide autogel in the treatment of patients with NETs. Specific adverse events, side effects, and potential risks associated with the use of lanreotide autogel are discussed, along with risk mitigation strategies and recommendations for patient monitoring.

EXPERT OPINION: The findings highlight the overall safety of lanreotide autogel in the management of NETs, with a focus on its efficacy in controlling hormone secretion, tumor progression, and symptom management. New safety concerns and precautions are also addressed to assist healthcare providers in making informed decisions when prescribing lanreotide autogel.




Medicine and Health Sciences




Department of Medicine, Cardiology Division, Fellows and Residents

Document Type